Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Kristalose, Constulose, Generlac, Enulose (1)

Analgesic (2) · Classic Psychedelic (1) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Research material (1) · [[:Category:Disaccharides|Non-absorbable disaccharide]] (1) · [[:Category:Hepatic_encephalopathy_treatments|Hepatic encephalopathy treatment]] (1) · [[:Category:Osmotic_laxatives|Osmotic laxative]] (1)

None (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Potent 5-HT2A agonist; no oral activity (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000F5C-QINU`"', '"`UNIQ--vote-00000F5D-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day (1)

None (2) · 10 g/15 mL solution (Constulose); 10 g, 20 g powder packets (Kristalose) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · Indication-specific; HE may require high-volume dosing (1)

None (2) · especially in acute HE) (1) · Oral (1) · PO (only formulation marketed in the US). (1) · rectal (enema (1)

None (2) · 30–60 min (PO) (1) · Constipation: 24-48 hours; HE: ammonia reduction within hours of stool production (1)

None (2) · 4–6 hours (1) · Hours (1)

None (2) · 2.5–3 hours (1) · Not meaningfully described — lactulose is not significantly absorbed (1)

None (2) · <3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)